$1,318.00
This Market Spotlight report covers the Systemic Lupus Erythematosus (SLE) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Systemic Lupus Erythematosus (SLE) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Disease definition
8 Symptoms
8 Patient subtypes
8 Risk factors
9 Diagnosis
10 TREATMENT
10 Nonsteroidal anti-inflammatory drugs (NSAIDs) and pain relievers
10 Corticosteroids
10 Antimalarial drugs
10 Immunosuppressive agents
11 Anticoagulants
11 Monoclonal antibodies
11 Repository corticotropin injection
12 EPIDEMIOLOGY
12 Summary
14 MARKETED DRUGS
17 PIPELINE DRUGS
25 RECENT EVENTS AND ANALYST OPINION
25 Cenerimod for SLE (November 1, 2021)
26 Olumiant for SLE (September 1, 2021)
27 Lenabasum for SLE (October 6, 2020)
30 KEY UPCOMING EVENTS
31 KEY REGULATORY EVENTS
31 SLE Treatment Among 13 New Drugs On Track For EU Approval
31 FDA Accepts ANI’s Refiled Cortophin Gel
31 AstraZeneca To Challenge GSK After Clinching Lupus Drug Approval
32 ANI Refiles Cortrophin After Talks With FDA
32 China Inc. Shines In Latest Batch Of Approvals
33 PROBABILITY OF SUCCESS
34 LICENSING AND ASSET ACQUISITION DEALS
34 Oak Hill To Build Upon Pair Of Phase II Candidates From Takeda
34 AstraZeneca And BenevolentAI Expand Collaboration
35 REVENUE OPPORTUNITY
36 CLINICAL TRIAL LANDSCAPE
37 Sponsors by status
38 Sponsors by phase
39 Recent events
41 BIBLIOGRAPHY
42 APPENDIX
LIST OF FIGURES
17 Figure 1: Overview of pipeline drugs for SLE in the US
17 Figure 2: Pipeline drugs for SLE, by company
18 Figure 3: Pipeline drugs for SLE, by drug type
18 Figure 4: Pipeline drugs for SLE, by classification
29 Figure 5: Lenabasum for SLE (October 6, 2020): Phase IIb – Pulmonary Exacerbations
30 Figure 6: Key upcoming events in SLE
33 Figure 7: Probability of success in the SLE pipeline
36 Figure 8: Clinical trials in SLE
36 Figure 9: Top 10 drugs for clinical trials in SLE
37 Figure 10: Top 10 companies for clinical trials in SLE
37 Figure 11: Trial locations in SLE
38 Figure 12: SLE trials status
39 Figure 13: SLE trials sponsors, by phase
LIST OF TABLES
15 Table 1: Marketed drugs for SLE
19 Table 2: Pipeline drugs for SLE in the US
25 Table 3: Cenerimod for SLE (November 1, 2021)
26 Table 4: Olumiant for SLE (September 1, 2021)
28 Table 5: Lenabasum for SLE (October 6, 2020)
35 Table 6: Historical global sales, by drug ($m), 2017–21
35 Table 7: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!